Policies to Impact, September 2024
Global Healthcare Innovation Alliance Accelerator (GHIAA)
Our vision: A world in which medical innovations are promptly available to all populations in need.
Welcome to the monthly newsletter from the Global Healthcare Alliance Accelerator (GHIAA)! You can also join our quarterly newsletter for a round-up of news delivered straight to your inbox, as well as follow us on LinkedIn and X for daily updates.
If you’ve read a post on our Linkedin page, you’ve already, in a way, met Britnae Purdy .
Britnae, GHIAA’s social media specialist, has been with the organization since early 2022. She learned about GHIAA through board member Beibei Sun .
“I knew Beibei from my time living in Durham, North Carolina, and I knew that any organization she was involved with was going to be doing good work. When she shared that GHIAA was looking for a social media specialist, I was immediately excited about gaining more experience in freelance communications and in global health equity.”
Britnae holds an MSc in Public Health from the London School of Hygiene and Tropical Medicine, U. of London , an MA in Global Affairs from George Mason University , and a BA in International Affairs/Women’s Studies from the University of Mary Washington . She is based just outside of Washington, D.C., where she also works for the Association of Public Health Laboratories. She has previously held freelance communication roles with several nonprofits, including First Peoples Worldwide, Stop Street Harassment, and Matador Network.
“I like helping people make connections,” she says of her work with GHIAA. “Public health is one big puzzle, and GHIAA holds some of the pieces people didn’t even know were missing.”
“I love when I can create something that draws new people toward our work. It’s really rewarding to make something that inspires people to become interested in a topic they hadn’t previously considered.”
CEPI – University of Oxford – Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
This Funding Agreement between CEPI, the University of Oxford, and Barinthus Biotherapeutics was signed in December 2023. The Agreement provides funding of up to $34.8 million to Barinthus Bio, in addition to funds previously committed to the University of Oxford, for the development of a MERS ChAdOx1 MERS vaccine candidate. The project will take the vaccine candidate from early development through Phase II clinical trials and potentially development of a ready reserve of investigational vaccines for deployment in a clinical trial setting in the event of disease outbreak.
Under the Agreement, CEPI will provide funding to the Partners (Oxford and Barinthus Bio) to undertake activities described in Work Packages. The funding is provided on a stage-gated basis, linked to the achievement of milestones. The Partners make commitments to equitable access principles including development and periodic update of an Equitable Access Plan (initially outlined in Annex E), affordable pricing in low- and middle-income countries, and technology transfer to selected manufacturers if needed to address outbreaks. The Agreement also includes the grant of a Public Health License to CEPI which may be exercised only under certain conditions for the purpose of achieving equitable access to the Project Vaccine.
领英推荐
Gates Foundation – Amyris, Inc., Malaria Therapeutic (artemisinin-based combination therapies – ACTs), Letter Agreement
This Letter Agreement between the Gates Foundation and Amyris was signed in April 2016. The Agreement is made in connection with a Stock Purchase Agreement for a $5 million investment in Amyris common stock by the Foundation. The proceeds of the investment may only be used for the development of a new, low-cost strain of yeast to produce artemisinic acid (AA) and amorphadiene (AD) for use in artemisinin-based combination therapies (ACTs) to treat malaria (“Project“).
The Project aims to reduce supply uncertainty and lower the cost of artemisinin for ACTs, particularly in developing countries. Under the Agreement, Amyris makes Global Access Commitments including: (i) supplying AA and AD at a price not exceeding COGS plus 10%; (ii) fulfilling orders up to 300 MT annually; (iii) ensuring downstream affordability for public sector purchasers; and (iv) a covenant not to enforce patents against third-party AA or AD manufacturers under certain circumstances.
The Global Access Commitments also include the grant of a royalty-free, worldwide, non-exclusive, sublicensable license to the Foundation under IP owned or licensed by Amyris to use, make or sell AA or AD solely for producing artemisinin for ACTs to treat malaria. Technology transfer materials will be held by an Escrow Agent and released to sublicensees upon the request of the Foundation.
Will you be joining us at the Licensing Executives Society (LES) USA & Canada Annual Meeting in New Orleans, October 20-23? Julie will moderate a workshop on Monday, October 21, titled "Bridging the Gap – Licensing Medical Technologies for Innovation and Global Equitable Access." Other panelists include Tara L. Kirby of the National Institutes of Health (NIH), Chan Park, General Counsel of the Medicines Patent Pool, Dr. Laleh Shayesteh of the University of California-Berkeley’s Office of Intellectual Property and Industry Research Alliances, and Lauren Sullivan of the Bill & Melinda Gates Foundation. This workshop will delve into the crucial intersection of licensing, technology transfer, and global health equity, especially in light of the lessons learned from the COVID-19 pandemic. Throughout the session, participants will have the opportunity to identify key challenges and best practices in licensing for global health impact, to exchange ideas and experiences with peers and experts from various sectors, and to gain practical guidance on leveraging licensing, funding opportunities, and strategic partnerships to maximize reach and impact in the post-pandemic landscape.?
What we’re reading:?
Questions? We’d love to hear from you at [email protected].
Thanks for spreading the news about our Annual Meeting! So excited to see you all in New Orleans. Global Healthcare Innovation Alliance Accelerator (GHIAA)